This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Merck And Regenstrief Institute Establish Evidence-Based Care Collaboration

Stocks in this article: MRK

The Regenstrief Institute and Merck, known as MSD outside the United States and Canada, have signed a five-year agreement to collaborate on a range of projects that will use clinical data to inform personalized delivery of health care. The work will explore novel methods for studying diseases and interventions for chronic conditions such as diabetes, cardiovascular disease and osteoporosis.

Ultimately, the Regenstrief-Merck collaboration seeks to improve the health of patients through data analytics, health care innovation, education and research that supports evidence-based health care.

Financial details were not disclosed.

“Regenstrief has a passion for determining how personalization of medicine can be achieved by better understanding and using health data,” said Regenstrief investigator and innovations officer Jon Duke, M.D., who serves as the institute’s lead investigator for the partnership. “Regenstrief brings rigorous science to clinical environments and has more than 40 years of experience as an international leader in improving health care delivery through informatics and health services research. With Merck’s depth of expertise and its global reach, we hope to develop and test new approaches to care, and advance successful models of health care broadly.” Dr. Duke also is an assistant professor of medicine at the Indiana University School of Medicine.

Both Regenstrief, a medical research organization closely associated with the Indiana University School of Medicine, and Merck, a global health care leader, are committed to generating new knowledge to improve health.

"This type of novel academic-industry collaboration can advance our understanding of a number of critical therapeutic areas, enabling novel use of health information technology to enhance drug development, medication safety and the personalization of therapeutics," said Sachin H. Jain, M.D., chief medical information and innovation officer at Merck.

Regenstrief Institute

An internationally respected informatics and health care research organization, the Regenstrief Institute is recognized for its role in improving quality of care, increasing efficiency of health care delivery, preventing medical errors and enhancing patient safety. Established in 1969, the institute is closely associated with the Indiana University School of Medicine and the Health and Hospital Corporation of Marion County.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,650.96 -21.64 -0.12%
S&P 500 2,050.54 -1.28 -0.06%
NASDAQ 4,755.8670 -2.0120 -0.04%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs